BofA raises target for Gilead Sciences stock to USD 164.00

Published on 10/16/2026 at 15:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Gilead releases third-quarter results on October 29, 2026. Gilead Sciences stock costs EUR 139.50 on October 16, 2026 at 3:39 p.m. CEST.

Investor dates and valuation

On October 12, 2026, BofA lifted its Gilead target from USD 162.00 to USD 164.00.
Gilead will release third-quarter results on October 29, 2026.
Gilead Sciences stock costs EUR 139.50 at Lang & Schwarz on October 16, 2026 at 3:39 p.m. CEST.
Gilead had a market capitalization of USD 193.9 billion and a P/E ratio of minus 58.60.

NASDAQ Handelssaal mit Biotech-Charts und Tradern für Gilead Sciences Aktie US3755581036 — Gilead Sciences NASDAQ Handelssaal ISIN US3755581036 Biotech-Sektor grüne Kerzencharts Trader digitale Bildschirme, Illustration mit AI erstellt.

Bank of America raised its price target for Gilead Sciences from USD 162.00 to USD 164.00 on October 12, 2026, while keeping a Buy rating, Investing.com reported. The new target stood 4.90 percent above Gilead's USD 156.34 Nasdaq price at 9:56 a.m. EDT on October 16, 2026. At Lang & Schwarz, Gilead Sciences stock was trading at EUR 139.50 on October 16, 2026 at 3:39 p.m. CEST.

BofA target reaches USD 164.00

The target revision keeps the analyst view tied to Gilead's commercial execution rather than to a new corporate announcement. Investing.com said BofA was modeling third-quarter Biktarvy sales of USD 3.922 billion against consensus of USD 3.908 billion, a USD 14.00 million difference. That estimate is separate from the target itself and gives investors a measurable operating reference for the October report.

October 29 results date

Gilead will release third-quarter 2026 results after the market closes on October 29, 2026, and management will host a webcast at 4:30 p.m. EDT. The date was announced by Gilead Sciences on October 15, 2026. The release is the next scheduled company event for the stock.

USD range and trading volume

Gilead's Nasdaq price of USD 156.34 sat within a 52-week range of USD 114.02 to USD 160.51 on October 16, 2026. The price was 2.60 percent below the high and 37.12 percent above the low. Trading volume reached 658,931 shares by 9:56 a.m. EDT, versus an average volume of 6,024,725 shares.

Valuation and peer comparison

Gilead's market capitalization was USD 193.9 billion, while its P/E ratio was minus 58.60 on October 16, 2026. The dividend yield was 0.02 percent in the same market snapshot.

Comparison with peers

Gilead Sciences: P/E minus 58.60, market capitalization USD 193.9 billion
Regeneron Pharmaceuticals (Nasdaq, USD): minus 0.06 percent, P/E 19.69, market capitalization USD 81.9 billion
Vertex Pharmaceuticals (Nasdaq, USD): minus 0.06 percent, P/E 29.60, market capitalization USD 128.9 billion

Euro quote in Berlin trading

The euro quotation places the German-market view below the USD 164.00 target after the October 12, 2026 revision. The next scheduled report on October 29, 2026 provides the next dated test for the sales assumptions cited by BofA.

Gilead Sciences stock was trading at EUR 139.50 at Lang & Schwarz on October 16, 2026 at 3:39 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Gilead Sciences stock.